Catia Marzolini

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


161 publications

In press | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
In press
 
Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir.
Marzolini C., Gibbons S., Seddon D., Khoo S. Expert opinion on drug metabolism & toxicology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8322AB5A633B]
 
Importance of Sex-Dependent Differences for Dosing Selection and Optimization of Chemotherapeutic Drugs.
Seydoux C., Briki M., Wagner A.D., Choong E., Guidi M., Carrara S., Thoma Y., Livio F., Girardin F.R., Marzolini C. et al. Chemotherapy. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_84F759610A36]
 
Is Non-Sustained Viral Suppression with Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug levels?
Thoueille P., Marzolini C., Guidi M., Cavassini M., Decosterd L.A. Clinical infectious diseases. Peer-reviewed.
[DOI][Pmid][serval:BIB_3FF55B9C536F]
2024
 
Ideal Time to Conduct a Pharmacokinetic Investigation After Delivery to Fully Capture the Effect of Pregnancy on Drug Exposure.
Berton M., Stader F., Bettonte S., Battegay M., Marzolini C., 2024/10. Open forum infectious diseases, 11 (10) pp. ofae585. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_885488F32325]
 
Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk.
Abela I.A., Chammartin F., Amstutz A., Surial B., Ballif M., Marzolini C., Aebi-Popp K., Notter J., Segeral O., Stoeckle M. et al., 2024/09. Open forum infectious diseases, 11 (9) pp. ofae502. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_40F9EA6FADDD]
 
Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study.
Bettonte S., Berton M., Stader F., Battegay M., Marzolini C., 2024/08/16. Clinical infectious diseases, 79 (2) pp. 477-486. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9B460E0DD4D0]
 
Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations.
Bongiovanni M., Thoueille P., Barda B., Mercier T., Marzolini C., Ramponi N., Choong E., Cantù M., Decosterd L.A., Bernasconi E., 2024/07. European journal of clinical microbiology & infectious diseases, 43 (7) pp. 1503-1504. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_798E811CC577]
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
Thoueille P., Saldanha S.A., Schaller F., Choong E., Veuve F., Munting A., Cavassini M., Braun D., Günthard H.F., Duran Ramirez J.J. et al., 2024/06. Clinical pharmacology and therapeutics, 115 (6) pp. 1450-1459. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A008171B295E]
Development of a physiologically-based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs.
Bettonte S., Berton M., Battegay M., Stader F., Marzolini C., 2024/05. CPT, 13 (5) pp. 781-794. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D188265E47AC]
Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study.
Bettonte S., Berton M., Stader F., Battegay M., Marzolini C., 2024/04. Open forum infectious diseases, 11 (4) pp. ofae171. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D14B6E2F8C73]
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update.
Briki M., Murisier A., Guidi M., Seydoux C., Buclin T., Marzolini C., Girardin F.R., Thoma Y., Carrara S., Choong E. et al., 2024/04/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1236 p. 124039. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC804B352E24]
Population pharmacokinetic analysis of doravirine in real-world people with HIV.
Thoueille P., Delarive L., Cavassini M., Buclin T., Decosterd L.A., Marzolini C., Girardin F.R., Guidi M., Swiss HIV Cohort Study, 2024/04. British journal of clinical pharmacology, 90 (4) pp. 1058-1065. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0E37EFB8FE58]
Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study.
Ambrosioni J., Díaz N.A., Marzolini C., Dragovic G., Imaz A., Calcagno A., Luque S., Curran A., Troya J., Tuset M. et al., 2024/03. Infectious diseases and therapy, 13 (3) pp. 609-617. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0F13E410DA20]
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures.
Thoueille P., Cavassini M., Guidi M., Buclin T., Girardin F.R., Decosterd L.A., Marzolini C., 2024/02. Open forum infectious diseases, 11 (2) pp. ofae023. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E70DD8E56C37]
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data.
Berton M., Bettonte S., Stader F., Decosterd L., Tarr P.E., Livio F., Cavassini M., Braun D.L., Kusejko K., Hachfeld A. et al., 2024/01/25. Clinical infectious diseases, 78 (1) pp. 98-110. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CE2036172D19]
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.
Thoueille P., Saldanha S.A., Schaller F., Choong E., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B. et al., 2024/01. The Lancet regional health. Europe, 36 p. 100793. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EE4919775F0F]
Vancomycin Dosing Strategy for the Treatment of Peritonitis in a Child on Automated Peritoneal Dialysis: A First Pediatric Case Report.
Haefliger D., Chehade H., Livio F., Rodrigues-Veiga V., Diezi L., Marzolini C., 2024. Seminars in dialysis, 37 (6) pp. 461-465. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_31FDA1A2A806]
2023
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen.
Bettonte S., Berton M., Stader F., Battegay M., Marzolini C., 2023/12. British journal of clinical pharmacology, 89 (12) pp. 3618-3628. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_248B4D9C065B]
 
Therapeutic drug monitoring of TB drugs
Choong Eva, Marzolini Catia, Girardin François, Decosterd Laurent, Köhler Niklas, 2023/12. dans Translational TB-Forum, Inselspital Bern, December 11, 2023. Peer-reviewed.
[serval:BIB_71F805AD727A]
 
Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
Sebastiani G., Milic J., Tsochatzis E.A., Marzolini C., Betel M., Bhagani S., Morse C.G., Cinque F., Maurice J.B., Ingiliz P. et al., 2023/11/01. Hepatology, 78 (5) pp. E87-E88. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_21CC4AD7AAEE]
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
Ambrosioni J., Levi L., Alagaratnam J., Van Bremen K., Mastrangelo A., Waalewijn H., Molina J.M., Guaraldi G., Winston A., Boesecke C. et al., 2023/11. HIV medicine, 24 (11) pp. 1126-1136. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2C3981328BD1]
Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study.
Schwenke J.M., Thorball C.W., Schoepf I.C., Ryom L., Hasse B., Lamy O., Calmy A., Wandeler G., Marzolini C., Kahlert C.R. et al., 2023/09/15. The Journal of infectious diseases, 228 (6) pp. 742-750. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_44F15B89FB36]
Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor-containing regimen.
Marzolini C., Cavassini M., Braun D.L., Hachfeld A., Bernasconi E., Calmy A., Schmid P., Battegay M., Elzi L., Swiss HIV Cohort Study, 2023/09. British journal of clinical pharmacology, 89 (9) pp. 2739-2746. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0B5571DA9173]
Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole.
Haefliger D., Marzolini C., Lamoth F., Pabst T., Buclin T., Livio F., 2023/07. British journal of clinical pharmacology, 89 (7) pp. 2304-2308. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9BC838D4B328]
Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers.
Berton M., Bettonte S., Stader F., Battegay M., Marzolini C., 2023/07. Open forum infectious diseases, 10 (7) pp. ofad361. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7B67BF5F2315]
Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates.
Bettonte S., Berton M., Stader F., Battegay M., Marzolini C., 2023/07. European journal of drug metabolism and pharmacokinetics, 48 (4) pp. 353-362. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_23ECE0BDE9E6]
Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study.
Avery E.F., Kleynhans J.N., Ledergerber B., Schoepf I.C., Thorball C.W., Kootstra N.A., Reiss P., Ryom L., Braun D.L., Thurnheer M.C. et al., 2023/06/08. Clinical infectious diseases, 76 (11) pp. 1969-1979. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E1546C7A7084]
Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient.
Erba A., Marzolini C., Rentsch K., Stoeckle M., Battegay M., Mayr M., Weisser M., 2023/05/05. Virology journal, 20 (1) p. 89. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1C2D4CA1C276]
Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years.
Schoepf I.C., Esteban-Cantos A., Thorball C.W., Rodés B., Reiss P., Rodríguez-Centeno J., Riebensahm C., Braun D.L., Marzolini C., Seneghini M. et al., 2023/05. The lancet. Healthy longevity, 4 (5) pp. e211-e218. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_689682CD15B9]
Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.
Bettonte S., Berton M., Stader F., Battegay M., Marzolini C., 2023/04/03. Clinical infectious diseases, 76 (7) pp. 1225-1236. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E90B3808E4B0]
 
Response to "A Case Report of Safe Coadministration of Amioradone With Short-Term Treatment Nirmatrelvir-Ritonavir".
Marzolini C., Khoo S., 2023/04. Clinical pharmacology and therapeutics, 113 (4) p. 770. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E2092A293875]
Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals.
Berton M., Bettonte S., Stader F., Battegay M., Marzolini C., 2023/02. Clinical pharmacokinetics, 62 (2) pp. 277-295. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D73E02992F11]
 
Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature.
Hodge D., Hodel E.M., Hughes E., Hazenberg P., Grañana Castillo S., Gibbons S., Wang D., Marra F., Marzolini C., Back D. et al., 2023/02/01. Journal of acquired immune deficiency syndromes, 92 (2) pp. 97-105. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_884753BED80A]
 
What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?
Bettonte S., Berton M., Marzolini C., 2023. Expert opinion on drug metabolism & toxicology, 19 (5) pp. 243-247. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FA8BB1B82639]
2022
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
Marzolini C., Kuritzkes D.R., Marra F., Boyle A., Gibbons S., Flexner C., Pozniak A., Boffito M., Waters L., Burger D. et al., 2022/12. Clinical pharmacology and therapeutics, 112 (6) pp. 1191-1200. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0A37FD0360C0]
Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.
Aebi-Popp K., Kahlert C.R., Crisinel P.A., Decosterd L., Saldanha S.A., Hoesli I., Martinez De Tejada B., Duppenthaler A., Rauch A., Marzolini C. et al., 2022/11/28. The Journal of antimicrobial chemotherapy, 77 (12) pp. 3436-3442. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_86A7D946ED7E]
Collaborative Challenges of Multi-Cohort Projects in Pharmacogenetics-Why Time Is Essential for Meaningful Collaborations.
Franchini F., Kusejko K., Marzolini C., Tellenbach C., Rossi S., Stampf S., Koller M., Stoyanov J., Möller B., Leichtle A.B., 2022/09/29. JMIR formative research, 6 (9) pp. e36759. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_45A10307821C]
Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus.
Jakeman B., Scherrer A.U., Darling KEA, Damas J., Bieler-Aeschlimann M., Hasse B., Schlosser L., Hachfeld A., Gutbrod K., Tarr P.E. et al., 2022/09. Open forum infectious diseases, 9 (9) pp. ofac457. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_06A5B894B7FF]
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
Ryom L., De Miguel R., Cotter A.G., Podlekareva D., Beguelin C., Waalewijn H., Arribas J.R., Mallon PWG, Marzolini C., Kirk O. et al., 2022/09. HIV medicine, 23 (8) pp. 849-858. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_63D4B2B09234]
Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models.
Berton M., Bettonte S., Stader F., Battegay M., Marzolini C., 2022/09. Clinical pharmacokinetics, 61 (9) pp. 1251-1270. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3C20802AF175]
 
Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.
Girardin F., Manuel O., Marzolini C., Buclin T., 2022/08. Clinical microbiology and infection, 28 (8) pp. 1044-1046. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_30CD844F1841]
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
Thoueille P., Alves Saldanha S., Schaller F., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B., Furrer H. et al., 2022/07/29. Pharmaceutics, 14 (8) p. 1588. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EA4A25E4F31E]
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.
Otten L.S., Piet B., van den Heuvel M.M., Marzolini C., van Geel RMJM, Gulikers J.L., Burger D.M., Leentjens J., Ter Heine R., 2022/06/30. European respiratory review, 31 (164). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_947C3642CB1E]
 
Sex-related pharmacokinetic differences with aging.
Stader F., Marzolini C., 2022/06. European geriatric medicine, 13 (3) pp. 559-565. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4A18657501DF]
 
Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years.
Schoepf I.C., Thorball C.W., Ledergerber B., Kootstra N.A., Reiss P., Raffenberg M., Engel T., Braun D.L., Hasse B., Thurnheer C. et al., 2022/05/04. The Journal of infectious diseases, 225 (9) pp. 1581-1591. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_39DB29D8297F]
Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV.
Zino L., Kingma J.S., Marzolini C., Richel O., Burger D.M., Colbers A., 2022/05. Clinical pharmacokinetics, 61 (5) pp. 619-635. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_514BD8F74357]
 
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.
Marzolini C., Kuritzkes D.R., Marra F., Boyle A., Gibbons S., Flexner C., Pozniak A., Boffito M., Waters L., Burger D. et al., 2022/05. Annals of internal medicine, 175 (5) pp. 744-746. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_70514994B951]
Magnitude of Drug-Drug Interactions in Special Populations.
Bettonte S., Berton M., Marzolini C., 2022/04/04. Pharmaceutics, 14 (4). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AC9B5EC9062F]
 
Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.
Marzolini C., Gibbons S., van Oosterhout J.J., Khoo S., 2022/03. Clinical pharmacokinetics, 61 (3) pp. 339-346. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C29D0A2BD9DD]
Fluvoxamine for the treatment of COVID-19.
Marzolini C., Marra F., Boyle A., Khoo S., Back D.J., 2022/03. The Lancet. Global health, 10 (3) pp. e331. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A6D6B687283D]
 
Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients.
Stader F., Battegay M., Sendi P., Marzolini C., 2022/03. Clinical pharmacology and therapeutics, 111 (3) pp. 579-584. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A0FD39599272]
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.
Jacobs T.G., Marzolini C., Back D.J., Burger D.M., 2022/02/23. The Journal of antimicrobial chemotherapy, 77 (3) pp. 568-573. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2B2E67F2149C]
 
Cohort Profile Update: The Swiss HIV Cohort Study (SHCS).
Scherrer A.U., Traytel A., Braun D.L., Calmy A., Battegay M., Cavassini M., Furrer H., Schmid P., Bernasconi E., Stoeckle M. et al., 2022/02/18. International journal of epidemiology, 51 (1) pp. 33-34j. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CAE07421BB63]
 
Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study.
Jakeman B., Scherrer A., Battegay M., Gunthard H.F., Hachfeld A., Calmy A., Schmid P., Bernasconi E., Cavassini M., Marzolini C., 2022/02/02. The Journal of antimicrobial chemotherapy, 77 (2) pp. 492-499. Peer-reviewed.
[DOI][Pmid][serval:BIB_9473F480CF4D]
2021
 
Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study.
Schoepf I.C., Thorball C.W., Ledergerber B., Engel T., Raffenberg M., Kootstra N.A., Reiss P., Hasse B., Marzolini C., Thurnheer C. et al., 2021/11/02. Clinical infectious diseases, 73 (9) pp. 1597-1604. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_782F7251FD8F]
Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
Stader F., Battegay M., Marzolini C., 2021/11. Clinical pharmacology and therapeutics, 110 (5) pp. 1231-1239. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_59A26B555DD0]
Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study.
Roth J.A., Radevski G., Marzolini C., Rauch A., Günthard H.F., Kouyos R.D., Fux C.A., Scherrer A.U., Calmy A., Cavassini M. et al., 2021/10/13. The Journal of infectious diseases, 224 (7) pp. 1198-1208. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_01426653908F]
 
Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors.
Deutschmann E., Bucher H.C., Jaeckel S., Gibbons S., McAllister K., Scherrer A.U., Braun D.L., Cavassini M., Hachfeld A., Calmy A. et al., 2021/10/05. Clinical infectious diseases, 73 (7) pp. e2145-e2152. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D84973BFC460]
Polypharmacy and risk of admission to hospital in people ageing with HIV: what is the contribution of drug-drug interactions?
Allavena C., Marzolini C., 2021/10. The lancet. Healthy longevity, 2 (10) pp. e606-e607. Peer-reviewed.
[DOI][Pmid][serval:BIB_5014773BE285]
 
Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study.
Kuemmerle A., Sikalengo G., Vanobberghen F., Ndege R.C., Foe G., Schlaeppi C., Burri C., Battegay M., Paris D.H., Glass T.R. et al., 2021/09/15. The Journal of antimicrobial chemotherapy, 76 (10) pp. 2681-2689. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_62DE667887F5]
Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature.
Hollinger A., Cueni N., Marzolini C., Dickenmann M., Landmann E., Battegay M., Martinez A.E., Siegemund M., Leuppi-Taegtmeyer A., 2021/09/04. AIDS research and therapy, 18 (1) p. 56. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_693CB6DBA95A]
Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.
Hodge D., Back D.J., Gibbons S., Khoo S.H., Marzolini C., 2021/07. Clinical pharmacokinetics, 60 (7) pp. 835-853. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_66D364242E0A]
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
Courlet P., Guidi M., Alves Saldanha S., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A., Csajka C., 2021/07. European journal of clinical pharmacology, 77 (7) pp. 979-987. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DCBBE5FFBE88]
Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre.
Istampoulouoglou I., Zimmermanns B., Grandinetti T., Marzolini C., Harings-Kaim A., Koechlin-Lemke S., Scholz I., Bassetti S., Leuppi-Taegtmeyer A.B., 2021/06/30. Global cardiology science & practice, 2021 (2) pp. e202111. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3291042AD159]
Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance.
Mari A., Roloff T., Stange M., Søgaard K.K., Asllanaj E., Tauriello G., Alexander L.T., Schweitzer M., Leuzinger K., Gensch A. et al., 2021/05/19. Microorganisms, 9 (5). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1343D3A3C14E]
Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
Stader F., Courlet P., Decosterd L.A., Battegay M., Marzolini C., 2021/04. Clinical pharmacology and therapeutics, 109 (4) pp. 1025-1029. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_04518947F853]
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
Courlet P., Guidi M., Alves Saldanha S., Stader F., Traytel A., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A. et al., 2021/03. Clinical pharmacokinetics, 60 (3) pp. 379-390. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CF76FDD25628]
 
Prescribing in COVID-19 patients: Should we take into account inflammation?
Marzolini C., Battegay M., Sendi P., Back D.J., 2021/03. British journal of clinical pharmacology, 87 (3) pp. 719-721. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_828321D63244]
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
Marra F., Smolders E.J., El-Sherif O., Boyle A., Davidson K., Sommerville A.J., Marzolini C., Siccardi M., Burger D., Gibbons S. et al., 2021/03. Drugs in R&D, 21 (1) pp. 9-27. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3B376E366BC1]
 
Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity.
Livio F., Deutschmann E., Moffa G., Rrustemi F., Stader F., Elzi L., Braun D.L., Calmy A., Hachfeld A., Cavassini M. et al., 2021/02/11. The Journal of antimicrobial chemotherapy, 76 (3) pp. 758-764. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4C33B6D1EDCD]
 
Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly.
Stader F., Courlet P., Kinvig H., Penny M.A., Decosterd L.A., Battegay M., Siccardi M., Marzolini C., 2021/02. Clinical pharmacology and therapeutics, 109 (2) pp. 471-484. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5CD39842E905]
 
Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation.
Stader F., Courlet P., Kinvig H., Battegay M., Decosterd L.A., Penny M.A., Siccardi M., Marzolini C., 2021/02. British journal of clinical pharmacology, 87 (2) pp. 458-470. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4429C140FFEE]
 
Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
Marzolini C., Stader F., Leuppi-Taegtmeyer A., Stoeckle M., Battegay M., Sendi P., 2021/02. Drug safety, 44 (2) pp. 255-257. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_087C444907D1]
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions.
Back D., Marzolini C., Hodge C., Marra F., Boyle A., Gibbons S., Burger D., Khoo S., 2021/01. British journal of clinical pharmacology, 87 (1) pp. 212-213. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BE885D4E98FF]
2020
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.
Hodge D., Marra F., Marzolini C., Boyle A., Gibbons S., Siccardi M., Burger D., Back D., Khoo S., 2020/12/01. The Journal of antimicrobial chemotherapy, 75 (12) pp. 3417-3424. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_08F605B4DD86]
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
Ryom L., Cotter A., De Miguel R., Béguelin C., Podlekareva D., Arribas J.R., Marzolini C., Mallon P., Rauch A., Kirk O. et al., 2020/11. HIV medicine, 21 (10) pp. 617-624. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0A40744EDF84]
Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
Bukkems V.E., Colbers A., Marzolini C., Molto J., Burger D.M., 2020/10. Clinical pharmacokinetics, 59 (10) pp. 1217-1236. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D038EEE13D3A]
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.
Stader F., Khoo S., Stoeckle M., Back D., Hirsch H.H., Battegay M., Marzolini C., 2020/10/01. The Journal of antimicrobial chemotherapy, 75 (10) pp. 3084-3086. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_43B047B70CB0]
 
Potentially inappropriate medications in older adults living with HIV.
López-Centeno B., Badenes-Olmedo C., Mataix-Sanjuan A., Bellón J.M., Pérez-Latorre L., López J.C., Benedí J., Khoo S., Marzolini C., Calvo-Alcántara M.J. et al., 2020/09. HIV medicine, 21 (8) pp. 541-546. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BE22A9BED55E]
 
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C., Stader F., Stoeckle M., Franzeck F., Egli A., Bassetti S., Hollinger A., Osthoff M., Weisser M., Gebhard C.E. et al., 2020/08/20. Antimicrobial agents and chemotherapy, 64 (9). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_52A2BDB2A614]
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
Courlet P., Decosterd L.A., Alves Saldanha S., Cavassini M., Stader F., Stoeckle M., Buclin T., Marzolini C., Csajka C., Guidi M. et al., 2020/08. Clinical pharmacokinetics, 59 (8) pp. 1037-1048. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B56252981556]
Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study.
López-Centeno B., Badenes-Olmedo C., Mataix-Sanjuan Á., McAllister K., Bellón J.M., Gibbons S., Balsalobre P., Pérez-Latorre L., Benedí J., Marzolini C. et al., 2020/07/11. Clinical infectious diseases, 71 (2) pp. 353-362. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_318B4B33A09A]
 
Real-life management of drug-drug interactions between antiretrovirals and statins.
Courlet P., Livio F., Alves Saldanha S., Scherrer A., Battegay M., Cavassini M., Stoeckle M., Decosterd L.A., Marzolini C., Swiss HIV Cohort Study, 2020/07/01. The Journal of antimicrobial chemotherapy, 75 (7) pp. 1972-1980. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_098C57274A05]
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Courlet P., Alves Saldanha S., Cavassini M., Marzolini C., Choong E., Csajka C., Günthard H.F., André P., Buclin T., Desfontaine V. et al., 2020/06. Journal of mass spectrometry, 55 (6) pp. e4506. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1D794571C1B2]
 
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Stader F., Decosterd L., Stoeckle M., Cavassini M., Battegay M., Saldanha S.A., Marzolini C., Courlet P., and the Swiss HIV Cohort Study, 2020/05/01. AIDS, 34 (6) pp. 949-952. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6666EE49EABD]
Cobicistat: A case of mislabelled drug-drug interaction risk?
Burger D.M., Calmy A., Marzolini C., 2020/05. British journal of clinical pharmacology, 86 (5) pp. 834-836. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B8DA1314B747]
 
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
Guaraldi G., Maurice J.B., Marzolini C., Monteith K., Milic J., Tsochatzis E., Bhagani S., Morse C.G., Price J.C., Ingiliz P. et al., 2020/05. Hepatology, 71 (5) pp. 1831-1844. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F4C60D19371B]
 
Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.
Stader F., Kinvig H., Penny M.A., Battegay M., Siccardi M., Marzolini C., 2020/03. Clinical pharmacokinetics, 59 (3) pp. 383-401. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FD484B6F37B1]
The challenge of HIV treatment in an era of polypharmacy.
Back D., Marzolini C., 2020/02. Journal of the International AIDS Society, 23 (2) pp. e25449. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F144619A662]
 
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P., Stader F., Guidi M., Alves Saldanha S., Stoeckle M., Cavassini M., Battegay M., Buclin T., Decosterd L.A., Marzolini C. et al., 2020/01/01. AIDS, 34 (1) pp. 103-108. Peer-reviewed.
[DOI][Pmid][serval:BIB_B80C7E3E1838]
 
Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study.
Schlaeppi C., Vanobberghen F., Sikalengo G., Glass T.R., Ndege R.C., Foe G., Kuemmerle A., Paris D.H., Battegay M., Marzolini C. et al., 2020/01. HIV medicine, 21 (1) pp. 53-63. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E19C31F9CB8A]
2019
 
Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A., Moss C.E., Marzolini C., Khoo S., 2019/12. Clinical pharmacokinetics, 58 (12) pp. 1553-1565. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_10F39D43477C]
Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV.
Courlet P., Livio F., Guidi M., Cavassini M., Battegay M., Stoeckle M., Buclin T., Alves Saldanha S., Csajka C., Marzolini C. et al., 2019/12. Open forum infectious diseases, 6 (12) pp. ofz531. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_747A12E6A2E6]
 
Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics.
Brockhaus L., Goldblum D., Eggenschwiler L., Zimmerli S., Marzolini C., 2019/11. Clinical microbiology and infection, 25 (11) pp. 1364-1369. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_489AF70B3BD9]
 
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al., 2019/09. British journal of clinical pharmacology, 85 (9) pp. 2022-2032. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F5C6318349C9]
 
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Courlet P., Spaggiari D., Desfontaine V., Cavassini M., Alves Saldanha S., Buclin T., Marzolini C., Csajka C., Decosterd L.A., 2019/09/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1125 p. 121733. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_00B59FADA800]
 
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.
Courlet P., Decosterd L.A., Brown J.A., Alves Saldanha S., Marzolini C., Cavassini M., Stoeckle M., Csajka C., Labhardt N.D., Calmy A. et al., 2019/08/01. The Journal of antimicrobial chemotherapy, 74 (8) pp. 2468-2470. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5082024839D9]
Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017.
Ruffieux Y., Lemsalu L., Aebi-Popp K., Calmy A., Cavassini M., Fux C.A., Günthard H.F., Marzolini C., Scherrer A., Vernazza P. et al., 2019/08. Journal of the International AIDS Society, 22 (8) pp. e25339. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3683258251EB]
A Comprehensive Framework for Physiologically-Based Pharmacokinetic Modeling in Matlab.
Stader F., Penny M.A., Siccardi M., Marzolini C., 2019/07. CPT, 8 (7) pp. 444-459. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EA04286016AB]
 
Prescribing issues in elderly individuals living with HIV.
Marzolini C., Livio F., 2019/07. Expert review of clinical pharmacology, 12 (7) pp. 643-659. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B259C3C07593]
 
Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes.
Stader F., Siccardi M., Battegay M., Kinvig H., Penny M.A., Marzolini C., 2019/04. Clinical pharmacokinetics, 58 (4) pp. 483-501. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_949E96735E90]
 
Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging.
Sundermann E.E., Erlandson K.M., Pope C.N., Rubtsova A., Montoya J., Moore A.A., Marzolini C., O'Brien K.K., Pahwa S., Payne BAI et al., 2019. AIDS research and human retroviruses, 35 (11-12) pp. 985-998. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_45929CA0F1E7]
 
Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV.
Hodel E.M., Marzolini C., Waitt C., Rakhmanina N., 2019. Current pharmaceutical design, 25 (5) pp. 556-576. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_922A080D3026]
Prescribing issues in older adults living with HIV: thinking beyond drug-drug interactions with antiretroviral drugs.
Livio F., Marzolini C., 2019. Therapeutic advances in drug safety, 10 p. 2042098619880122. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EFDEC7A79125]
2018
 
Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods.
Baettig V., Courlet P., Delko T., Battegay M., Marzolini C., 2018/08/24. AIDS, 32 (13) pp. 1903-1905. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F02FAD94EE15]
Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.
Stader F., Kinvig H., Battegay M., Khoo S., Owen A., Siccardi M., Marzolini C., 2018/07. Antimicrobial agents and chemotherapy, 62 (7). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F8C50E7725D6]
Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0.
Ryom L., Boesecke C., Bracchi M., Ambrosioni J., Pozniak A., Arribas J., Behrens G., Mallon P., Puoti M., Rauch A. et al., 2018/05. HIV medicine, 19 (5) pp. 309-315. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_81AA6FF34456]
 
Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry.
Courlet P., Spaggiari D., Cavassini M., Du Pasquier R., Alves Saldanha S., Buclin T., Marzolini C., Csajka C., Decosterd L., 2018/04. Clinical mass spectrometry, 8 pp. 8-20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4B32461DFE9C]
 
HIV and Aging - Perhaps Not as Dramatic as We Feared?
Engel T., Raffenberg M., Marzolini C., Cavassini M., Kovari H., Hasse B., Tarr P.E., 2018. Gerontology, 64 (5) pp. 446-456. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_92146D8F7DD2]
2017
 
Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.
Marzolini C., Decosterd L., Winterfeld U., Tissot F., Francini K., Buclin T., Livio F., 2017/12. British journal of clinical pharmacology, 83 (12) pp. 2835-2838. Peer-reviewed.
[DOI][Pmid][serval:BIB_80C3490C172B]
Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems.
Erb S., Letang E., Glass T.R., Natamatungiro A., Mnzava D., Mapesi H., Haschke M., Duthaler U., Berger B., Muri L. et al., 2017/10. HIV medicine, 18 (9) pp. 623-634. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_08EF5DFFC9F0]
 
Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
Bartels H., Decosterd L., Battegay M., Marzolini C., 2017/09/01. The Journal of antimicrobial chemotherapy, 72 (9) pp. 2574-2577. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C9AD206973FE]
 
Dolutegravir plasma levels after gastric bypass surgery.
Piso R.J., Battegay M., Marzolini C., 2017/04/24. AIDS, 31 (7) pp. 1052-1054. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B68D2496A89]
 
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C., Rajoli R., Battegay M., Elzi L., Back D., Siccardi M., 2017/04. Clinical pharmacokinetics, 56 (4) pp. 409-420. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9F18F66D9DEB]
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection.
Seden K., Gibbons S., Marzolini C., Schapiro J.M., Burger D.M., Back D.J., Khoo S.H., 2017. PloS one, 12 (3) pp. e0173509. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7E2E6A799E25]
2016
Privacy-preserving genomic testing in the clinic: a model using HIV treatment.
McLaren P.J., Raisaro J.L., Aouri M., Rotger M., Ayday E., Bartha I., Delgado M.B., Vallet Y., Günthard H.F., Cavassini M. et al., 2016/08. Genetics in medicine, 18 (8) pp. 814-822. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C52D051D158A]
 
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
Marzolini C., Gibbons S., Khoo S., Back D., 2016/07. The Journal of antimicrobial chemotherapy, 71 (7) pp. 1755-1758. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DC583F272754]
 
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis.
Scherrer A.U., von Wyl V., Yang W.L., Kouyos R.D., Böni J., Yerly S., Klimkait T., Aubert V., Cavassini M., Battegay M. et al., 2016/05/15. Clinical infectious diseases, 62 (10) pp. 1310-1317. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B3E6EC9A4633]
2015
 
Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma.
Kurz M., Stoeckle M., Krasniqi F., Battegay M., Marzolini C., 2015/03. International journal of STD & AIDS, 26 (3) pp. 212-214. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_83F16B0032D8]
 
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.
Marzolini C., Sabin C., Raffi F., Siccardi M., Mussini C., Launay O., Burger D., Roca B., Fehr J., Bonora S. et al., 2015/01/14. AIDS, 29 (2) pp. 193-200. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7EACCBC2761B]
 
Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.
Moss D.M., Marzolini C., Rajoli R.K., Siccardi M., 2015. Expert opinion on drug metabolism & toxicology, 11 (8) pp. 1203-1217. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_456E26B8BF12]
2014
 
Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus.
Lakatos B., Stoeckle M., Elzi L., Battegay M., Marzolini C., 2014/01/22. Swiss medical weekly, 144 pp. w13906. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_42F980B2A895]
Obesity trends and body mass index changes after starting antiretroviral treatment : the Swiss HIV Cohort Study
Hasse B., Iff M., Ledergerber B., Calmy A., Schmid P., Hauser C., Cavassini M., Bernasconi E., Marzolini C., Tarr P.E. et al., 2014. Open Forum Infectious Diseases, 1 (2) pp. ofu040.
[URN][DOI][Pmid][serval:BIB_44F79E67FED2]
2013
 
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
Siccardi M., Marzolini C., Seden K., Almond L., Kirov A., Khoo S., Owen A., Back D., 2013/07. Clinical pharmacokinetics, 52 (7) pp. 583-592. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FD8C145BB564]
 
The brain entry of HIV-1 protease inhibitors is facilitated when used in combination.
Marzolini C., Mueller R., Li-Blatter X., Battegay M., Seelig A., 2013/06/03. Molecular pharmaceutics, 10 (6) pp. 2340-2349. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0C13E1E15CAD]
 
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R., Arab-Alameddine M., Rotger M., Fayet-Mello A., Martinez R., Guidi M., di Iulio J., Cavassini M., Günthard H.F., Furrer H. et al., 2013. Pharmacogenetics and Genomics, 23 (1) pp. 9-18. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CDA03D8C1D2B]
2012
Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.
Glass T.R., Rotger M., Telenti A., Decosterd L., Csajka C., Bucher H.C., Günthard H.F., Rickenbach M., Nicca D., Hirschel B. et al., 2012/01. Plos One, 7 (1) pp. e29186. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5217BD6F9449]
 
Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing.
de Roche M., Siccardi M., Stoeckle M., Livio F., Back D., Battegay M., Marzolini C., 2012. Antiviral therapy, 17 (7) pp. 1381-1384. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2B532405FD6A]
 
Maternal antiretroviral prophylaxis and breastfeeding.
Marzolini C., Gray G.E., 2012. Antiviral therapy, 17 (8) pp. 1503-1506. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF7BF57F3E84]
 
Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.
Siccardi M., Almond L., Schipani A., Csajka C., Marzolini C., Wyen C., Brockmeyer N.H., Boffito M., Owen A., Back D., 2012. Clinical Pharmacology and Therapeutics, 92 (4) pp. 494-502.
[DOI][WoS][Pmid][serval:BIB_974D19D0A162]
2011
 
Medikamenteninteraktion bei HIV-Therapien [Drug-drug interactions with HIV treatments]
Mossdorf E., Marzolini C., Fasel D., Mello Fayet A., Blum C., Donath M., Battegay M., 2011/09/21. Praxis, 100 (19) pp. 1193-1196. Peer-reviewed.
[DOI][Pmid][serval:BIB_46F353253623]
Ageing with HIV: medication use and risk for potential drug-drug interactions.
Marzolini C., Back D., Weber R., Furrer H., Cavassini M., Calmy A., Vernazza P., Bernasconi E., Khoo S., Battegay M. et al., 2011. Journal of Antimicrobial Chemotherapy, 66 (9) pp. 2107-2111.
[URN][DOI][WoS][Pmid][serval:BIB_91EDE0960CA0]
2010
 
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R., di Iulio J., Fayet A., Colombo S., Martinez R., Marzolini C., Furrer H., Vernazza P., Calmy A., Cavassini M. et al., 2010. Pharmacogenetics and Genomics, 20 (4) pp. 217-230.
[DOI][WoS][Pmid][serval:BIB_F0BE883DE124]
 
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.
Marzolini C., Elzi L., Gibbons S., Weber R., Fux C., Furrer H., Chave J.P., Cavassini M., Bernasconi E., Calmy A. et al., 2010. Antiviral Therapy, 15 (3) pp. 413-423.
[DOI][WoS][Pmid][serval:BIB_6BCAC526F0B2]
 
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Elzi L., Marzolini C., Furrer H., Ledergerber B., Cavassini M., Hirschel B., Vernazza P., Bernasconi E., Weber R., Battegay M. et al., 2010. Archives of Internal Medicine, 170 (1) pp. 57-65.
[DOI][WoS][Pmid][serval:BIB_FFDD9D2AEA04]
2009
 
Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.
Mertz D., Battegay M., Marzolini C., Mayr M., 2009/07. American journal of kidney diseases, 54 (1) pp. e1-4. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_47690AB48B71]
2008
 
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity.
Krishnamurthy P., Schwab M., Takenaka K., Nachagari D., Morgan J., Leslie M., Du W., Boyd K., Cheok M., Nakauchi H. et al., 2008/07/01. Cancer research, 68 (13) pp. 4983-4989. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B46C08CD3C0B]
2007
 
A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression.
Marzolini C., Tirona R.G., Gervasini G., Poonkuzhali B., Assem M., Lee W., Leake B.F., Schuetz J.D., Schuetz E.G., Kim R.B., 2007/08. Molecular endocrinology, 21 (8) pp. 1769-1780. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B63F6D18F6AD]
2006
 
Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.
Colombo S., Béguin A., Marzolini C., Telenti A., Biollaz J., Decosterd L.A., 2006/02. Journal of Chromatography. B, 832 (1) pp. 138-143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_240D221E7E2F]
 
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
Ribaudo H.J., Haas D.W., Tierney C., Kim R.B., Wilkinson G.R., Gulick R.M., Clifford D.B., Marzolini C., Fletcher C.V., Tashima K.T. et al., 2006/02/01. Clinical infectious diseases, 42 (3) pp. 401-407. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F8F912D966CB]
2005
 
Placental transfer of antiretroviral drugs.
Marzolini C., Kim R.B., 2005/08. Clinical pharmacology and therapeutics, 78 (2) pp. 118-122. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1F1B7FFB4CA3]
 
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.
Fellay J., Marzolini C., Decosterd L., Golay K.P., Baumann P., Buclin T., Telenti A., Eap C.B., 2005. European journal of clinical pharmacology, 60 (12) pp. 865-73. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7E60EAA242E4]
2004
 
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
Haas D.W., Ribaudo H.J., Kim R.B., Tierney C., Wilkinson G.R., Gulick R.M., Clifford D.B., Hulgan T., Marzolini C., Acosta E.P., 2004/12/03. AIDS, 18 (18) pp. 2391-2400. Peer-reviewed.
[WoS][Pmid][serval:BIB_FBA7F629F387]
 
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction
Colombo S., Guignard N., Marzolini C., Telenti A., Biollaz J., Decosterd L. A., 2004/10. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 810 (1) pp. 25-34.
[DOI][WoS][Pmid][serval:BIB_21D53DE5F776]
 
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
Csajka C., Marzolini C., Fattinger K., Décosterd L.A., Telenti A., Biollaz J., Buclin T., 2004/09. Antimicrobial agents and chemotherapy, 48 (9) pp. 3226-3232. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1C445DFD3180]
 
Pharmacogenomics of the OATP and OAT families.
Marzolini C., Tirona R.G., Kim R.B., 2004/04. Pharmacogenomics, 5 (3) pp. 273-282. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_56B4D87BEB7A]
 
MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment.
Bleiber G., May M., Suarez C., Martinez R., Marzolini C., Egger M., Telenti A., Swiss HIV Cohort Study, 2004/02/15. The Journal of infectious diseases, 189 (4) pp. 583-586. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4344DC6AC930]
 
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini Catia, Paus Erik, Buclin Thierry, Kim Richard B., 2004. Clinical Pharmacology and Therapeutics, 75 (1) pp. 13-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_111D08D8358F]
2003
 
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C., Marzolini C., Fattinger K., Décosterd L.A., Fellay J., Telenti A., Biollaz J., Buclin T., 2003. Clinical pharmacology and therapeutics, 73 (1) pp. 20-30. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_39A9FD8E09B3]
2002
 
Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery.
Marzolini C., Béguin A., Telenti A., Schreyer A., Buclin T., Biollaz J., Decosterd L.A., 2002/07/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 774 (2) pp. 127-140. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE146774859E]
 
Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients.
Doser N., Kübli S., Telenti A., Marzolini C., Chave J.P., Feihl F., Buclin T., Pannatier A., Darioli R., Nicod P. et al., 2002. AIDS, 16 (14) pp. 1982-3. Peer-reviewed.
[Pmid][serval:BIB_477361CA79FF]
 
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G. et al., 2002. The Lancet, 359 (9300) pp. 30-36. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_15EF32DDF0CC]
 
Transplacental passage of protease inhibitors at delivery.
Marzolini C., Rudin C., Decosterd L.A., Telenti A., Schreyer A., Biollaz J., Buclin T., 2002. AIDS, 16 (6) pp. 889-893. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_24752]
2001
 
Impaired absorption of rifabutin by concomitant administration of didanosine.
Marzolini C., Chave J.P., Telenti A., Brenas-Chinchon L., Biollaz J., 2001/11/09. AIDS, 15 (16) pp. 2203-2204. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8EE75DE9A92B]
 
Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.
Marzolini C., Buclin T., Decosterd L.A., Biollaz J., Telenti A., 2001/08. Therapeutic drug monitoring, 23 (4) pp. 394-398. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AFB4A7406A45]
 
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., Buclin T., 2001. AIDS, 15 (1) pp. 71-75. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_84CEAFA7373C]
 
Rôle du suivi thérapeutique des concentrations d'antirétroviraux dans la prise en charge des patients HIV
Marzolini C., Décosterd L. A., Buclin T., Telenti A., Biollaz J., 2001. Médecine et Hygiène, 59 (2369) pp. 2302-2305.
[serval:BIB_9C38267673ED]
2000
 
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction
Marzolini C., Telenti A., Buclin T., Biollaz J., Decosterd L. A., 2000/03. Journal of Chromatography. B, Biomedical Sciences and Applications, 740 (1) pp. 43-58.
[DOI][WoS][Pmid][serval:BIB_645EE36B1BB1]
 
Efavirenz decreases methadone blood concentrations.
Marzolini C., Troillet N., Telenti A., Baumann P., Decosterd L.A., Eap C.B., 2000. AIDS, 14 (9) pp. 1291-1292. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3264B6C2D4B7]
1999
 
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Gander M., Leyvraz S., Decosterd L., Bonfanti M., Marzolini C., Shen F., Liénard D., Perey L., Colella G., Biollaz J. et al., 1999/07. Annals of oncology, 10 (7) pp. 831-838. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6B773617CF43]
1998
 
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C., Decosterd L.A., Shen F., Gander M., Leyvraz S., Bauer J., Buclin T., Biollaz J., Lejeune F., 1998. Cancer Chemotherapy and Pharmacology, 42 (6) pp. 433-440.
[DOI][WoS][Pmid][serval:BIB_7BB2FAA8F76D]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University